Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased MiMedx Group, Inc. (“MiMedx” or the “Company”) (NasdaqCM:MDXG) common stock between October 26, 2011 and September 4, 2013.
For more information, click here: http://zlk.9nl.com/mimedx-group-mdxg/.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (a) the Company violated the Public Health Service Act by unlawfully manufacturing and marketing certain unapproved biologics products; and (b) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.
On September 4, 2013, MiMedx acknowledged the receipt of a letter from the Food and Drug Administration (“FDA”) which stated that MiMedx’s Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing and marketing drugs at one of its plants. On this news, MiMedx securities fell more than 36%, to close at $3.85 per share on September 4, 2013.If you suffered a loss in MiMedx you have until November 8, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/mimedx-group-mdxg/. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts